Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classement en actions
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Prix de l'action
$4.87
Capitalisation boursière
$4.36B
Changement (1 jour)
-5.47%
Changement (1 an)
-15.62%
Pays
CN
Échange Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Catégorie
Healthcare
Revenus pour Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd de 2006 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $600.18M | 267.03% |
| 2024 | $163.52M | 14.15% |
| 2023 | $143.25M | 19.70% |
| 2022 | $119.67M | -18.11% |
| 2021 | $146.13M | 45.75% |
| 2020 | $100.27M | -40.70% |
| 2019 | $169.09M | 1.82% |
| 2018 | $166.06M | -2.09% |
| 2017 | $169.60M | 22.48% |
| 2016 | $138.47M | 2.49% |
| 2015 | $135.11M | 7.86% |
| 2014 | $125.26M | 4.39% |
| 2013 | $119.99M | 25.65% |
| 2012 | $95.50M | 26.69% |
| 2011 | $75.38M | 45.08% |
| 2010 | $51.96M | 44.63% |
| 2009 | $35.92M | 53.80% |
| 2008 | $23.36M | 84.39% |
| 2007 | $12.67M | 186.16% |
| 2006 | $4.43M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $10.11B | - |
BE
|
|
| $6.02B | - |
NL
|
